{{Drugbox
| IUPAC_name = 3-(5,6-dihydrobenzo[b][f]benzazepin- 11-yl)- ''N'',''N''-dimethyl- propan- 1-amine ''N''-oxide
| image = Imipraminoxide skeletal.svg
| alt = Skeletal formula of imipraminoxide
| width = 200
| image2 = Imipraminoxide-3D-balls.png
| alt2 = Ball-and-stick model of the imipraminoxide molecule

<!--Clinical data-->
| tradename = Imiprex, Elepsin
| pregnancy_category = 
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = [[Intravenous therapy|Intravenous]]: 1.8 hours<ref name="Dörwald2013">{{cite book|author=Florencio Zaragoza Dörwald|title=Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds|url=https://books.google.com/books?id=YTeY9ZEfNccC&pg=PA311|date=4 February 2013|publisher=John Wiley & Sons|isbn=978-3-527-64565-7|pages=311–}}</ref>
| excretion = 

<!--Identifiers-->
| CAS_number = 6829-98-7
| ATC_prefix = N06
| ATC_suffix = AA03
| ChEMBL = 1614644
| PubChem = 65589
| ChemSpiderID = 59031
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 8MKS280XJW
| KEGG = D07334

<!--Chemical data-->
| C=19 | H=24 | N=2 | O=1 
| molecular_weight = 296.41 g/mol
}}

'''Imipraminoxide''' (brand names '''Imiprex''', '''Elepsin'''), or '''imipramine ''N''-oxide''', is a [[tricyclic antidepressant]] (TCA) that was introduced in [[Europe]] in the 1960s for the treatment of [[Major depressive disorder|depression]].<ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | page = 546 | isbn = 3-88763-075-0 | oclc = | doi = | url = https://books.google.com/books?id=5GpcTQD_L2oC&lpg=PA1389&dq=imipraminoxide&as_brr=3&pg=PA546#v=onepage&q=&f=false}}</ref><ref name="isbn0-412-54090-8">{{cite book | title = Dictionary of organic compounds | publisher = Chapman & Hall | location = London | year = 1996 | page = 3877 | isbn = 0-412-54090-8 | oclc = | doi = | url = https://books.google.com/books?id=rWt8RTCJK1EC&lpg=PA3877&dq=imipraminoxide&as_brr=3&pg=PA3877#v=onepage&q=imipraminoxide&f=false}}</ref><ref name="pmid13944543">{{cite journal |vauthors=FAURBYE A, JACOBSEN O, KRISTJANSEN P, MUNKVAD I | title = Imipramine-N-oxide: preliminary investigation of a new antidepressive drug | journal = The American Journal of Psychiatry | volume = 120 | issue = | pages = 277–8 |date=September 1963 | pmid = 13944543 | doi = | url = http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=13944543}}</ref><ref name="pmid5133241">{{cite journal | author = Lingjaerde O | title = [Imiprex "Dumex" (imipramine oxide). A new tricyclic antidepressive agent] | language = Norwegian | journal = Tidsskrift for Den Norske Lægeforening : Tidsskrift for Praktisk Medicin, Ny Række | volume = 91 | issue = 31 | pages = 2267–8 |date=November 1971 | pmid = 5133241 | doi = | url = }}</ref>

Imipraminoxide is both an [[Structural analog|analogue]] and a [[metabolite]] of [[imipramine]], and has similar effects.<ref name="pmid4572170">{{cite journal |vauthors=Rapp W, Norén MB, Pedersen F | title = Comparative trial of imipramine N-oxide and imipramine in the treatment of out-patients with depressive syndromes | journal = Acta Psychiatrica Scandinavica | volume = 49 | issue = 1 | pages = 77–90 | year = 1973 | pmid = 4572170 | doi = 10.1111/j.1600-0447.1973.tb04400.x| url = }}</ref><ref name="isbn0-444-53266-8">{{cite book | author = Aronson, Jeffrey Kenneth | title = Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects) | publisher = Elsevier Science | location = Amsterdam | year = 2008 | page = 34 | isbn = 0-444-53266-8 | oclc = | doi = | url = https://books.google.com/books?id=s0XYvuPVgaAC&lpg=PP1&dq=imipraminoxide&as_brr=3&pg=PA34#v=onepage&q=&f=false}}</ref><ref name="pmid4947298">{{cite journal | author = Dencker SJ | title = [Clinical trial with imipramine-N-oxide and amitriptyline-N-oxide] | language = Swedish | journal = Nordisk Psykiatrisk Tidsskrift. Nordic Journal of Psychiatry | volume = 25 | issue = 5 | pages = 463–70 | year = 1971 | pmid = 4947298 | doi = | url = }}</ref><ref name="isbn0-7817-3481-9">{{cite book |author1=Beale, John Marlowe |author2=Wilson, Charles Henry |author3=Gisvold, Ole |author4=Block, John H. | title = Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry | publisher = Lippincott Williams & Wilkins | location = Hagerstwon, MD | year = 2004 | page = 87 | isbn = 0-7817-3481-9 | oclc = | doi = | url = https://books.google.com/books?id=CeibVy3-LSMC&lpg=PA87&dq=%22imipramine%20N-oxide%22&as_brr=3&pg=PA87#v=onepage&q=%22imipramine%20N-oxide%22&f=false}}</ref> However, in [[clinical trial]]s, imipraminoxide was found to have a faster onset of action, slightly higher efficacy, and fewer and less marked [[side effect]]s, including diminished [[orthostatic hypotension]] and [[anticholinergic]] effects like [[dry mouth]], [[sweating]], [[dizziness]], and [[Fatigue (medical)|fatigue]].<ref name="pmid4572170"/><ref name="isbn0-444-53266-8"/><ref name="pmid4947298"/><ref name="isbn0-7817-3481-9"/><ref name="pmid952235">{{cite journal |vauthors=Dencker SJ, Bake B | title = Investigation of the orthostatic reaction after intravenous administration of imipramine, chlorimipramine, and inimpramine-N-oxide | journal = Acta Psychiatrica Scandinavica | volume = 54 | issue = 1 | pages = 74–8 |date=July 1976 | pmid = 952235 | doi = 10.1111/j.1600-0447.1976.tb00095.x| url = }}</ref><ref name="pmid6427827">{{cite journal |vauthors=Clemmesen L, Mikkelsen PL, Lund H, Bolwig TG, Rafaelsen OJ | title = Assessment of the anticholinergic effects of antidepressants in a single-dose cross-over study of salivation and plasma levels | journal = Psychopharmacology | volume = 82 | issue = 4 | pages = 348–54 | year = 1984 | pmid = 6427827 | doi = 10.1007/BF00427684| url = }}</ref>

Imipraminoxide's [[pharmacology]] has not been well elucidated, but based on its very close relationship with imipramine, it likely acts as a [[serotonin reuptake inhibitor|serotonin]] and [[norepinephrine reuptake inhibitor]] and [[serotonin receptor|serotonin]], [[adrenergic receptor|adrenenaline]], [[histamine receptor|histamine]], and [[muscarinic acetylcholine receptor]] [[receptor antagonist|antagonist]], though with weaker [[antiadrenergic]] and [[anticholinergic]] actions.<ref name="pmid952235"/><ref name="pmid6427827"/>

Imipraminoxide has been said to be a [[prodrug]] of imipramine.<ref name="AnzenbacherZanger2012">{{cite book|author1=Pavel Anzenbacher|author2=Ulrich M. Zanger|title=Metabolism of Drugs and Other Xenobiotics|url=https://books.google.com/books?id=f-XHh17NfwgC&pg=PA302|date=23 February 2012|publisher=John Wiley & Sons|isbn=978-3-527-64632-6|pages=302–}}</ref>

==See also==
* [[Amitriptylinoxide]]

==References==
{{Reflist|30em}}

{{Antidepressants}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Histamine receptor modulators}}
{{Monoamine reuptake inhibitors}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Amine oxides]]
[[Category:Dibenzazepines]]
[[Category:Muscarinic antagonists]]
[[Category:Tricyclic antidepressants]]


{{nervous-system-drug-stub}}